Last updated: April 23, 2026
Who Supplies Lisinopril to the Global Drug Market?
Lisinopril is an established, off-patent angiotensin-converting enzyme (ACE) inhibitor used in hypertension and heart failure. Supply is dominated by large generics and specialty ingredient manufacturers that provide (1) active pharmaceutical ingredient (API) and (2) finished-dose tablets for brand and generic channels. Because lisinopril is typically sold as generic product in many markets, supplier lists are fragmented across geographies and rely on regulatory listings (FDA Orange Book for products; FDA’s Drug Registration and Listing System for firms; and DMFs/ADFs for API manufacturers).
Which firms supply lisinopril API (manufacturers of the active ingredient)?
API supply is commonly traced through Drug Master Files (DMFs) submitted to the U.S. FDA. A practical supplier map for investors and sourcing teams is built from: (a) FDA DMF holders for “lisinopril” and (b) associated API manufacturer sites listed in FDA registration dossiers.
Core API supply channels (by firm type):
- DMF holders: firms that maintain the FDA DMF for lisinopril API and authorize downstream manufacture.
- Contract API manufacturers: sites that produce for one or more DMF holders under tolling or quality agreements.
- Intermediates suppliers: upstream manufacturers that supply key chemical intermediates used to synthesize lisinopril (often via multi-step synthesis).
How suppliers are identified in regulatory records (U.S.-centric):
- FDA Orange Book identifies finished-dose products and their manufacturers/labelers.
- FDA Drug Registration and Listing System identifies product registrants.
- FDA DMFs identify API manufacturing entities. (API DMF holders and/or manufacturing sites can differ.)
Which companies sell lisinopril finished tablets (U.S. drug products/labelers)?
Finished-dose lisinopril tablet supply in the U.S. includes many generic companies. Supplier selection for contracting depends on the exact strength (e.g., 2.5 mg, 5 mg, 10 mg, 20 mg), dosage form, and whether the product is “AB” rated to the reference listed drug.
U.S. finished-dose sourcing is typically verified by:
- FDA Orange Book entries for lisinopril tablets (active ingredients and rating status).
- FDA product registration listing records for the specific National Drug Code (NDC).
What is the practical supplier landscape (concentration and sourcing implications)?
Lisinopril supply concentrates across a few dominant generic platforms because:
- The molecule is mature and widely manufactured.
- Quality systems and regulatory compliance determine approvals.
- Sourcing is frequently managed through established API-to-finished-dose supply chains.
What sourcing teams usually optimize for:
- DMF-backed API availability (to reduce lead-time and compliance gaps).
- Global manufacturing footprint (to manage recalls and capacity shocks).
- Inspection history and compliance status of the API and finished-dose sites.
- Batch release testing capability (impurity profile, stereochemistry/related substances).
Which regulatory sources provide the authoritative supplier list?
A “supplier list” that holds up in diligence is built from FDA databases, not marketing catalogs.
Authoritative U.S. data sources:
- FDA Orange Book: identifies lisinopril drug products and the listed manufacturers/labelers for each NDC.
- FDA Drug Registration and Listing (DRLS): identifies registrants by labeler.
- FDA DMF database (and the DMF itself): identifies lisinopril API DMF holders and authorized manufacturing sites.
- FDA publicly available product and facility information for compliance cross-checking.
What does an actionable procurement pathway look like for lisinopril?
For procurement and technical transfer, teams typically run a two-layer check:
- Finished-dose contract (verify manufacturer and NDC listing through Orange Book and DRLS).
- API verification (verify which DMF holder(s) and manufacturing sites support the finished-dose product’s API).
This avoids mismatches where the finished-dose labeler differs from the API DMF holder.
Key Takeaways
- Lisinopril supplier identification is best done through FDA Orange Book (finished products) and FDA DMF/DRLS (API and registrants) rather than reseller lists.
- The supply chain is usually platform-driven: a limited set of API and finished-dose systems support many generics.
- For diligence, procurement should validate (1) labeler and NDC and (2) API DMF holder and manufacturing site to prevent quality and lead-time risk.
FAQs
1) Who are the “suppliers” for lisinopril in practice?
Suppliers fall into two categories: API manufacturers (DMF holders/sites) and finished-dose tablet manufacturers/labelers supplying specific NDCs.
2) How do I verify an API supplier for lisinopril?
Use FDA records: identify the lisinopril API DMF holder/manufacturing site and link it to the finished-dose product’s labeler through NDC listings.
3) What determines whether a lisinopril product is sourceable from a specific company?
Availability tied to the exact strength and dosage form, plus whether the company’s NDC is active and listed in FDA systems.
4) Why do API and finished-dose suppliers often differ?
Because many finished-dose manufacturers source API under contracts from DMF-authorized API producers.
5) Where do I find the most defensible supplier list for diligence?
FDA’s Orange Book (finished-dose) and DMF/DRLS (API and registrants) are the most direct sources.
References
[1] U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] U.S. Food and Drug Administration. Drug Registration and Listing System (DRLS). https://www.fda.gov/drugs/drug-registration-and-listing-system-drls
[3] U.S. Food and Drug Administration. Drug Master Files (DMF). https://www.fda.gov/drugs/drug-master-files-dmfs
